Is Atypical Lipomatous Tumor Cancer or Benign?

Atypical lipomatous tumor (ALT) is classified as a low-grade malignancy, placing it squarely in the uncomfortable space between harmless and dangerous. It almost never spreads to distant organs, which is the hallmark behavior people associate with cancer, yet it can grow back after removal and, in a small fraction of cases, transform into a more aggressive tumor. The label itself was designed to reflect that in-between biology, but the terminology around these tumors has created real confusion for patients and even among clinicians.

Why the Name Matters More Than Usual

ALT and “well-differentiated liposarcoma” (WDL) describe the same tumor under a microscope. The cells look identical, and the genetic changes driving them are the same. The difference in name reflects where the tumor sits in the body, not what it is biologically. ALT is the preferred term for tumors in the limbs and superficial soft tissue, where surgical removal tends to be straightforward and outcomes are favorable. WDL is reserved for the same tumor when it grows in the retroperitoneum (the deep space behind the abdominal organs), the chest cavity, or the pelvis, where complete removal is harder and the clinical course is more serious.¹

This dual-naming system has real consequences. A meta-analysis looking at how these tumors are labeled in pathology reports, research papers, and clinical guidelines found that the interchangeable use of ALT and WDL creates confusion that can lead to unnecessarily aggressive treatment for low-risk limb tumors or, conversely, overly casual follow-up for deep-body tumors that carry genuine metastatic potential.² If your pathology report says “well-differentiated liposarcoma” and the tumor was in your thigh, that does not automatically mean you have a more dangerous tumor than someone whose report says “atypical lipomatous tumor.” It may just mean your pathologist used the older or alternative term.

How ALT Differs from an Ordinary Lipoma

A lipoma is a benign lump of fat cells. It is one of the most common soft-tissue growths in adults, and the vast majority never cause problems beyond the occasional cosmetic annoyance or mild discomfort if they press on a nerve. ALT grows from fat tissue too, but the cells carry genetic abnormalities that a regular lipoma does not. The most important of these is amplification of a gene called MDM2, often accompanied by amplification of CDK4. These extra gene copies drive the tumor’s low-grade malignant behavior and are the single most reliable way to tell ALT apart from a benign lipoma.³

Under a microscope, pathologists look for cells with enlarged, irregular, darkly staining nuclei, features that would be unusual in an ordinary lipoma.⁴ But the microscopic overlap between a large lipoma and an ALT can be subtle enough that pathologists sometimes need molecular confirmation. That is where fluorescence in situ hybridization (FISH) testing comes in. FISH looks directly at the tumor’s chromosomes for extra copies of MDM2. In one retrospective study of liposarcomas, MDM2 amplification was found in the liposarcoma cases but not in any of the benign lipomas or other benign fat tumors tested.³ Newer RNA-based tests have been proposed as alternatives, though they can sometimes produce misleading results in certain benign lipoma variants and are not yet considered a full replacement for FISH.⁵

What Imaging Can and Cannot Tell You

MRI is the standard imaging tool for evaluating fatty tumors. Certain features on a scan raise suspicion that a fatty lump is ALT rather than a simple lipoma. The presence of thick internal dividing walls (septa) is one of the strongest indicators. In one study comparing lipomas and ALTs on MRI, the vast majority of lipomas either had no septa or only thin ones under two millimeters, while most ALTs had septa and a substantial portion had septa at or above that threshold.⁶ Another study found that having thick septa increased the likelihood of ALT by roughly sixfold.⁷

Other red flags on imaging include a tumor larger than ten centimeters, globular non-fatty areas or solid-looking masses within the fatty tissue, and a composition that is less than three-quarters fat. In a large imaging review, the presence of non-fatty masses within the lesion increased the statistical likelihood of malignancy by 32-fold, making it the single strongest imaging predictor identified.⁸ That said, imaging alone cannot make a definitive diagnosis. Plenty of benign lipomas are large, and some ALTs look relatively bland on MRI. Molecular testing of the tissue after biopsy or excision remains the gold standard.

The Real Risk: Dedifferentiation

The reason ALT cannot simply be dismissed as benign, despite its slow growth and near-zero metastatic rate, is the possibility of dedifferentiation. This means the tumor transforms over time into a higher-grade sarcoma with genuinely aggressive behavior. A dedifferentiated liposarcoma can spread to the lungs and other distant sites, carrying a metastatic potential in the range of 15 to 20 percent. Roughly one in ten ALTs undergoes this transformation.⁹

Dedifferentiation does not happen overnight. In the case report from which that figure is drawn, the transformation occurred twelve years after the tumor was first detected. This long timeline is characteristic: ALTs tend to recur locally over years, and it is often a recurrence rather than the initial tumor that shows dedifferentiated areas. The risk is highest for retroperitoneal tumors, where complete surgical removal is more difficult. For limb tumors, dedifferentiation is less common but still warrants long-term monitoring.

Surgery and How Much Tissue to Remove

Surgery is the primary treatment for ALT. The central question surgeons face is how aggressively to cut. A “wide resection” removes the tumor along with a generous cuff of normal tissue, while a “marginal resection” removes the tumor just at or near its edges. For high-grade sarcomas, wide margins are standard because the risk of leaving behind microscopic disease is high. For ALT, the calculus is different because the tumor is low-grade and located in limbs where removing large amounts of tissue can damage muscles, nerves, and blood vessels.

A comparative study found that an “expanded marginal excision,” where surgeons take a deliberate but modest margin around the tumor rather than a wide resection, provided local control rates that were not inferior to wide resection, while avoiding the greater morbidity that comes with removing more tissue.¹⁰ Another single-center analysis supported marginal resection as offering an acceptable recurrence rate while preserving critical structures and function, provided that patients are followed regularly afterward.¹¹ The trend in limb ALT management has shifted toward less aggressive surgery combined with closer surveillance, rather than the radical operations that once would have been standard for anything labeled “liposarcoma.”

Location within the limb also seems to matter. One study found that patients with ALTs in the lower limb had significantly lower local recurrence rates, which could influence how aggressively those patients need to be followed after surgery.¹²

When ALT Sits Deep in the Abdomen

Retroperitoneal ALT (typically called WDL in this location) is a fundamentally different clinical problem. These tumors often grow very large before causing symptoms because there is so much space in the abdomen. Complete surgical removal frequently requires taking out adjacent organs like a kidney or part of the colon. Even after aggressive surgery, recurrence rates are substantially higher than for limb tumors.

For patients who do develop a recurrence in the retroperitoneum, the decision about when and whether to reoperate is not straightforward. Research on salvage surgery for recurrent retroperitoneal well-differentiated liposarcoma suggests that rushing back into the operating room after detecting a recurrence may not always provide a benefit. Strategic watchful waiting, monitoring the recurrence carefully and intervening only when there are clear signs of growth or dedifferentiation, may be a more thoughtful approach for selected patients.¹³

The Role of Radiation Therapy

For most limb ALTs, surgery alone is considered sufficient. But radiation therapy enters the conversation in specific situations, particularly when a tumor has recurred or when the margins after surgery are positive or close. A multicenter evaluation of adjuvant radiation after first-time resection of extremity ALT found that it significantly reduced local recurrence, but at a cost: complication rates roughly tripled compared to surgery alone.¹⁴ Those complications include wound healing problems, joint stiffness, and long-term tissue fibrosis, issues that matter greatly when the tumor is near a joint or in an area critical for daily function.

For recurrent or residual ALT, a combination of re-excision and radiation has shown promise in providing long-term local control with acceptable side effects. Pre-operative radiation at standard doses appears to be effective and generally well-tolerated in this setting.¹⁵ The bottom line is that radiation works but involves a real trade-off, and most clinicians reserve it for situations where the recurrence risk is judged to outweigh the complications.

What Follow-Up Looks Like

Because ALT can recur years or even a decade after removal, long-term follow-up is essential. The focus of surveillance is detecting local recurrence early. MRI of the surgical site at regular intervals is the mainstay. The multicenter radiation study referenced above specifically recommended a ten-year follow-up window for extremity ALT patients, reflecting just how late recurrences can appear.¹⁴

One question patients often have is whether they need regular chest scans to check for lung metastases, the way patients with higher-grade sarcomas do. Research suggests that chest imaging adds little value in the surveillance of ALTs that have not recurred locally. Since ALT itself has a near-zero metastatic rate, the recommendation is to focus imaging on the primary site and reserve chest surveillance for patients who develop local recurrence or in whom dedifferentiation is suspected.¹⁶ This is a meaningful practical distinction from higher-grade sarcomas, where routine chest imaging is standard care.

Functional Outcomes After Treatment

ALTs in the thigh can grow remarkably large before they are found, sometimes reaching twenty centimeters or more. Patients understandably worry about how much function they will lose after surgery for a tumor that big. A case series of patients with giant thigh ALTs found that the vast majority experienced improved limb function after surgical removal, with over 90 percent showing measurable gains in their ability to walk, climb stairs, and carry out daily activities.¹⁷ The tumor itself, by compressing surrounding muscles and nerves, often causes more functional impairment than the surgery to remove it does.

Tumors That Mimic ALT

Not every fatty tumor with unusual-looking cells under the microscope turns out to be ALT. Hibernomas, a rare benign tumor made of brown fat cells, can closely mimic ALT on biopsy. A study of 64 hibernomas that histologically resembled ALT emphasized the importance of distinguishing between the two, because the clinical management is completely different: hibernomas are benign and do not recur after simple removal.¹⁸ MDM2 FISH testing reliably separates the two, since hibernomas lack the gene amplification that defines ALT.

Dysplastic lipomas, a variant of benign lipoma with some atypical-looking cells, also sit in the diagnostic gray zone. These are particularly relevant because newer RNA-based molecular tests can sometimes flag dysplastic lipomas as positive, creating a false impression of ALT. Traditional FISH testing does not have this problem and remains the more reliable way to rule ALT in or out.⁵

Drug Therapies on the Horizon

Surgery is currently the only curative treatment for ALT, and systemic chemotherapy has historically been ineffective against well-differentiated fatty tumors. However, the same genetic changes that define ALT, the amplification of MDM2 and CDK4, also provide potential drug targets. MDM2 inhibitors aim to restore the function of a tumor-suppressing protein that MDM2 normally keeps in check, while CDK4 inhibitors block a protein that helps drive cell division. Several of these drugs have entered clinical trials for liposarcomas.¹⁹ Results so far have been more promising for dedifferentiated disease than for pure ALT, and none of these agents are yet standard of care. But for patients whose tumors are unresectable or have dedifferentiated, these targeted approaches represent the first plausible systemic treatment options the field has had.